Companies/Hyperfine, Inc.

Company profile

Hyperfine, Inc.

NASDAQ: HYPR · Healthcare · Medical - Specialties

PublicHQ Guilford, CTCIK 0001833769Reports USD

#591 of 1,394 Healthcare companies by revenue49th-percentile growth

EA Score

44D

FH 45DQ 40GM 49SS 49

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, 3-yr revenue growth · ↓ listing tenure, growth stability

Methodology →

Revenue TTM

$15.3M

Rev growth YoY (TTM)

+30.7%

Net income (FY)

-$35.6M

Employees

102

Market cap

$109.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$13.6M$13.6M2025

Net income-$35.6M-$35.6M2025

Operating income-$37.1M-$37.1M2025

Total assets$55.3M$55.3M2025

Liabilities$14.3M$14.3M2025

Equity$41.0M$41.0M2025

Revenue trend

FY2021 – FY2025 · USD

$294.0k

FY21

$1.5M

FY21

$6.8M

FY22

$11.0M

FY23

$12.9M

FY24

$13.6M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product84%

Service16%

By geography

Non-US100%

The read

Hyperfine, Inc. booked $13.6M in FY2025 revenue, growing 5.2% year over year — about the middle of the pack among Healthcare companies we track, at a -262.3% net margin.

Peers · Healthcare

Lucid Diagnostics Inc.35D Exagen Inc.55C QT Imaging Holdings, Inc.40D Anixa Biosciences, Inc.52D

Key facts

CEOMaria Degois Sainz

SectorHealthcare

IndustryMedical - Specialties

HeadquartersGuilford, CT

ExchangeNASDAQ: HYPR

Employees102

IPO date2021-01-28

Latest filings

8-K2026-05-21 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-08 8-K2026-03-18 8-K2026-03-18 10-K2026-03-18 8-K2026-01-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.